

1 **Variants of concern are overrepresented among post-vaccination breakthrough infections of**
2 **SARS-CoV-2 in Washington State**

3
4 Abbye E. McEwen¹, Seth Cohen², Chloe Bryson-Cahn², Catherine Liu³, Steven A. Pergam³, John
5 Lynch², Adrienne Schippers⁴, Kathy Strand⁴, Estella Whimbey², Nandita S Mani², Allison J.
6 Zelikoff⁵, Vanessa A. Makarewicz⁵, Elizabeth R. Brown³, Shah A. Mohamed Bakhsh¹, Noah R.
7 Baker¹, Jared Castor¹, Robert J. Livingston¹, Meei-Li Huang¹, Keith R. Jerome^{1,3}, Alexander L.
8 Greninger^{1,3*}, Pavitra Roychoudhury^{1,3*#}

9
10 ¹ Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA,
11 USA

12 ² Division of Allergy and Infectious Diseases, Department of Medicine, University of
13 Washington, Seattle, WA, USA

14 ³ Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle,
15 WA, USA

16 ⁴ Department of Infection Prevention and Employee Health, University of Washington Medical
17 Center, Seattle, WA, USA

18 ⁵ Harborview Medical Center, University of Washington, Seattle, WA, USA

19
20 *co-senior authors

21 #Corresponding author

22 Pavitra Roychoudhury, proychou@uw.edu

23 1100 Fairview Ave N, E5-110, Seattle WA 98109-1024, USA

24 Phone: 206-616-4948

25

26 Keywords: SARS-CoV-2, vaccine breakthrough, variants of concern, sequencing

27

28 **Abstract**

29 Across 20 vaccine breakthrough cases detected at our institution, all 20 (100%) infections were
30 due to variants of concern (VOC) and had a median Ct of 20.2 (IQR=17.1-23.3). When compared
31 to 5174 contemporaneous samples sequenced in our laboratory, VOC were significantly
32 enriched among breakthrough infections ($p < .05$).

33

34

35 **Main text**

36 Vaccination against SARS-CoV-2 elicits an immune response capable of potentially neutralizing the
37 virus. Multiple SARS-CoV-2 vaccines have been approved for use in humans through emergency
38 use authorization or are in phase 3 clinical trials. Most of these vaccines use a recombinant
39 spike protein derived from the first sequenced (Wuhan) strain from January 2020. The most
40 widely used vaccines (mRNA-based mRNA-1273 and BNT162b2) have shown up to 95% efficacy
41 at preventing clinical cases and up to 100% efficacy in preventing severe disease [1]. However,
42 there is growing concern that emerging variants may escape vaccine-induced immunity and
43 result in breakthrough infections in fully vaccinated individuals [2].

44 Since emerging in humans, SARS-CoV-2 is now defined by a variety of lineages harboring
45 distinctive genetic changes in the spike protein. Variants of concern (VOCs) are those strains
46 that show evidence of increased transmissibility, more severe disease, reduced neutralization
47 by antibodies elicited by past infection or vaccination, reduced efficacy of treatments, or
48 failures in diagnostic detection. As of May 20, 2021, there are currently 4 VOC identified by the
49 US SARS-CoV-2 Interagency Group (P.1, B.1.351, B.1.427, and B.1.429) that show reduced
50 neutralization by convalescent and post-vaccination sera [3].

51 Although *in vitro* studies have shown that some variants of concern are less effectively
52 neutralized by sera from vaccinated individuals [4], the clinical implications for post-vaccination
53 breakthrough infection remain largely unknown. In this study, we examined SARS-CoV-2
54 genomes isolated from individuals identified as vaccine breakthrough cases and compared
55 them to the background of SARS-CoV-2 sequences from Washington over the same time
56 interval.

57

58 **Methods**

59 This work was approved by the University of Washington (UW) Institutional Review Board. The
60 UW Virology Lab (UWVL) routinely performs SARS-CoV-2 whole genome sequencing of
61 specimens received for clinical testing. In this study, cases were defined as patients who were

62 fully vaccinated against SARS-CoV-2 (> two weeks post-2nd dose of Pfizer or Moderna vaccine)
63 who subsequently tested positive by RT-PCR. The control group included samples collected in
64 WA from the same time period as the case samples that were sequenced at UWVL. SARS-CoV-2
65 was detected by RT-PCR as previously described using either the emergency use-authorized UW
66 CDC-based laboratory-developed test, Hologic Panther Fusion or Roche Cobas SARS-CoV-2 tests
67 [5]. Sequencing was attempted on all specimens with Ct < 36 using a multiplexed amplicon
68 sequencing panel from Swift Biosciences [6] or Illumina COVIDSeq (Illumina Inc, USA).
69 Consensus sequences were assembled using a custom bioinformatics pipeline described
70 previously (https://github.com/greninger-lab/covid_swift_pipeline, [6]). We excluded SARS-
71 CoV-2 genome sequences that were incomplete (length < 29kbp) or of low quality (>10% Ns).
72 SARS-CoV-2 lineages and clades were assigned using the PANGOLIN (Phylogenetic Assignment
73 of Named Global Outbreak LINeages, <https://pangolin.cog-uk.io/>) and NextClade
74 (<https://clades.nextstrain.org/>) tools. Amino acid changes were annotated according to
75 NextClade. Analysis and calculations were performed in R. Significant differences in case
76 distributions according to variants of concern were determined using Fisher's exact test.

77

78 **Results**

79 Beginning in February 2021, SARS-CoV-2 genome sequencing was requested at UW Medicine
80 hospitals and partners as part of investigations into post-vaccine breakthrough infections. A
81 total of 20 cases were sequenced in this study, including 13 females, 6 males, and 1 with
82 unknown sex. Ages ranged from 26 to 65 years (median=43, IQR=28-58) (Supplementary Table
83 1), and Ct values ranged from 16.00 to 35.86 (median=20.2, IQR=17.1-23.3). These specimens
84 were collected between February 23 and April 27, 2021. The control group consisted of
85 genomes sequenced by UWVL (n=5174) during the same period as the vaccine breakthrough
86 cohort (Supplementary Table 1).

87 All 20 of 20 vaccine breakthrough cases were classified as variants of concern: 8 (40%)
88 B.1.1.7, 1 (5%) B.1.351, 2 (10%) B.1.427, 8 (40%) B.1.429, and 1 (5%) P.1 (Figure 1A,
89 Supplementary Table 2). In contrast, during the same time interval, 68% of WA cases

90 sequenced at UWVL represented VOC with 31% B.1.1.7, 1% B.1.351, 3% B.1.427, 27% were
91 B.1.429, and 7% were P.1 (Figure 1B). Overall, variants of concern were proportionally over-
92 represented in breakthrough cases, with the frequency of all VOCs in breakthrough increased
93 1.47-fold compared to the control group (95% CI [1.45, 1.50], $p=0.001$). Variants B.1.427,
94 B.1.429, and B.1.1.7 were 3.38-fold (95% CI [0.90, 12.71], $p=0.119$), 1.51-fold (95% CI [0.88,
95 2.59], $p=0.203$), and 1.29-fold (95% CI [0.75, 2.20], $p=0.468$) more common in breakthrough
96 cases compared to controls (Supplementary Figure 1, Supplementary Table 2). The overall
97 distribution of variants was significantly different between breakthrough and control groups (p
98 = 0.001, Fisher's Exact test, Supplementary Table 2). Variants that have been reported to be less
99 effectively neutralized by antibodies from post-vaccinated individuals (P.1, B.1.351, B.1.427,
100 and B.1.429) were identified in 60% of breakthrough cases and 36.7% of control cases, a 1.63-
101 fold change (95% CI [1.14, 2.34], $p=0.037$).

102 We compared the occurrence of individual mutations in spike in the breakthrough vs.
103 control groups. A single mutation, W258L, was 15.22-fold enriched in breakthrough cases, 95%
104 CI [3.91, 59.10], $p=0.008$ (Fig. 1D), but was present in only 2 cases. No other mutations showed
105 significant enrichment in the breakthrough group.

106 Clinical data, including comorbidities and vaccination type and dates ($n=19$), were
107 available for a subset of subjects (Supplementary Table 3). All patients received mRNA-based
108 vaccines (14 BNT162b2, 5 mRNA-1273); 15 out of 18 reported symptoms, none required
109 hospitalization. Specimens were collected at an average of 67.7 days after vaccination
110 (range=39-112, $sd=18.1$).

111

112 Discussion

113 In this study, SARS-CoV-2 variants of concern were found to be overrepresented in vaccine
114 breakthrough cases when compared to cases circulating in the general population of
115 Washington State over the same time interval. Although no single VOC was significantly
116 enriched in the breakthrough cases, subgroup analysis revealed that variants that have shown
117 reduced antibody neutralization *in vitro* (B.1.351, B.1.427, B.1.429, and P1) were

118 overrepresented compared to the B.1.1.7 VOC lineage which is not associated with reduced
119 neutralization. The 20 vaccine breakthrough cases described here also had a substantially
120 stronger viral load than 22 breakthrough cases among Chicago nursing facility staff and
121 residents recently reported by the CDC [7].

122 The B.1.427/B.1.429 variants were first identified in Los Angeles County, California in
123 July of 2020 [8] and quickly became the dominant form of the virus circulating in that state.
124 These variants were first seen in Washington State in December 2020 and comprised 30% of
125 cases during the study period. The B.1.427/B.1.429 variants are characterized by key spike
126 protein changes, with L452R in receptor binding domain and S13C and W152C in the N-terminal
127 domain (NTD). Recent studies suggest that neutralizing antibody titers from plasma collected
128 from vaccinated or convalescent individuals were reduced 2-7 fold against B.1.427/B.1.429
129 variant relative to wildtype [8,9]. Similarly, P.1 variant identified in Brazil and B.1.351 variant
130 identified in South Africa also show reduced antibody neutralization efficiency, 4-5 and 5-40
131 fold, respectively [10,11]. Both P.1 and B.1.351 were uncommon in the control group, with P.1
132 comprising 6% of cases and B.1.351 less than 1% of cases. In contrast, the B.1.1.7 variant, first
133 identified in the United Kingdom and known to increase infectivity by approximately 50%, is
134 neutralized as efficiently as wild type or only minimally decreased in most studies [11–13].
135 B.1.1.7 was the major variant circulating in our area during the study period. While it is noted
136 that the introduction of E484K into the B.1.1.7 background has been shown to introduce
137 reduced neutralization efficiency [14], this mutation was not present in any of our
138 breakthrough B.1.1.7 cases, so we considered this strain as having similar neutralization
139 efficiency as wild-type. These data therefore suggest that *in vitro* neutralization assays may
140 predict variants more likely to escape antibodies from vaccinated individuals.

141 Most mutations thought to lead to antibody neutralization resistance occur in the
142 receptor binding domain of the spike protein [15]. Of note, 2 of 2 B.1.427 cases identified in the
143 breakthrough group contained a spike mutation W258L outside of the receptor binding domain,
144 compared to 50 of 208 (24.03%) in the control group. W258L resides in the so called “NTD-
145 antigen supersite”. While antibodies that bind the receptor binding domain may target
146 different epitopes, a single site of vulnerability to antibody neutralization exists in the NTD [16].

147 The impact of NTD alterations in antibody neutralization efficiency is largely unstudied. Our
148 data suggest that *in vitro* studies of antibody neutralization residence should include NTD
149 alterations such as W258L.

150 This study is limited by the small number of subjects in the vaccine breakthrough group,
151 and we cannot exclude the presence of additional breakthrough cases in the control groups due
152 to a lack of clinical data. Moreover, our breakthrough cohort was mostly composed of
153 healthcare workers who were identified by infection control or employee health. In contrast,
154 sequences from UWVL were sampled from across the state and include samples from various
155 testing sites including hospitals, outpatient clinics, and community testing sites.

156 All 20 breakthrough cases in this study were assigned a lineage without conflicts. This
157 contrasts with a recent study which demonstrated a novel variant in a post-vaccination
158 individual that fell between clades 20B and 20C, raising concern that viral evolution may drive
159 neutralization antibody resistance [2]. Continued surveillance of post-vaccine breakthrough
160 cases may help target variants of concern for inclusion in new or booster SARS-CoV-2 vaccines.

161

162 **Acknowledgements**

163 Computational analyses were made possible by Scientific Computing Infrastructure at Fred
164 Hutch and UW Laboratory Medicine IT cloud infrastructure.

165

166 **Funding**

167 This work is supported by the National Institutes of Health [ORIP grant S10OD028685 to
168 Scientific Computing at Fred Hutch, and UW-Fred Hutch CFAR AI027757 to P.R.].

169

170 **Conflicts of Interest**


171 A.L.G. reports contract testing from Abbott Laboratories and research support from Gilead and
172 Merck, outside of the described work.

173

174 **References**

- 175 1. Funk CD, Laferrière C, Ardakani A. Target product profile analysis of COVID-19 vaccines in
176 Phase III clinical trials and beyond: An early 2021 perspective. *Viruses* **2021**; 13:418.
- 177 2. Hacisuleyman E, Hale C, Saito Y, et al. Vaccine breakthrough infections with SARS-CoV-2
178 variants. *N Engl J Med* **2021**; Available at: <http://dx.doi.org/10.1056/NEJMoa2105000>.
- 179 3. CDC. SARS-CoV-2 Variant Classifications and Definitions. 2021. Available at:
180 [https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html)
181 [info.html](https://www.cdc.gov/coronavirus/2019-ncov/cases-updates/variant-surveillance/variant-info.html). Accessed 19 May 2021.
- 182 4. Garcia-Beltran WF, Lam EC, St Denis K, et al. Multiple SARS-CoV-2 variants escape
183 neutralization by vaccine-induced humoral immunity. *Cell* **2021**; 184:2523.
- 184 5. Nalla AK, Casto AM, Huang M-LW, et al. Comparative Performance of SARS-CoV-2
185 Detection Assays Using Seven Different Primer-Probe Sets and One Assay Kit. *J Clin*
186 *Microbiol* **2020**; 58. Available at: <http://dx.doi.org/10.1128/JCM.00557-20>.
- 187 6. Addetia A, Lin MJ, Peddu V, Roychoudhury P, Jerome KR, Greninger AL. Sensitive recovery
188 of complete SARS-CoV-2 genomes from clinical samples using Swift Biosciences' SARS-CoV-
189 2 multiplex amplicon sequencing panel. *J Clin Microbiol* **2020**; Available at:
190 <http://dx.doi.org/10.1128/JCM.02226-20>.
- 191 7. Teran RA, Walblay KA, Shane EL, et al. Postvaccination SARS-CoV-2 infections among
192 skilled nursing facility residents and staff members - Chicago, Illinois, December 2020-
193 march 2021. *MMWR Morb Mortal Wkly Rep* **2021**; 70:632–638.


- 194 8. Deng X, Garcia-Knight MA, Khalid MM, et al. Transmission, infectivity, and neutralization of
195 a spike L452R SARS-CoV-2 variant. *Cell* **2021**; Available at:
196 <http://dx.doi.org/10.1016/j.cell.2021.04.025>.
- 197 9. Shen X, Tang H, Pajon R, et al. Neutralization of SARS-CoV-2 variants B.1.429 and B.1.351.
198 *N Engl J Med* **2021**; Available at: <http://dx.doi.org/10.1056/NEJMc2103740>.
- 199 10. Wang P, Casner RG, Nair MS, et al. Increased resistance of SARS-CoV-2 variant P.1 to
200 antibody neutralization. *Cell Host Microbe* **2021**; Available at:
201 <http://dx.doi.org/10.1016/j.chom.2021.04.007>.
- 202 11. Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and
203 B.1.1.7. *Nature* **2021**; 593:130–135.
- 204 12. Shen X, Tang H, McDanal C, et al. SARS-CoV-2 variant B.1.1.7 is susceptible to neutralizing
205 antibodies elicited by ancestral spike vaccines. *Cell Host Microbe* **2021**; 29:529-539.e3.
- 206 13. Edara VV, Floyd K, Lai L, et al. Infection and mRNA-1273 vaccine antibodies neutralize
207 SARS-CoV-2 UK variant. *medRxiv* **2021**; Available at:
208 <http://dx.doi.org/10.1101/2021.02.02.21250799>.
- 209 14. Collier DA, De Marco A, Ferreira IATM, et al. Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA
210 vaccine-elicited antibodies. *Nature* **2021**; 593:136–141.
- 211 15. Focosi D, Maggi F. Neutralising antibody escape of SARS-CoV-2 spike protein: Risk
212 assessment for antibody-based Covid-19 therapeutics and vaccines. *Rev Med Virol* **2021**;
213 Available at: <http://dx.doi.org/10.1002/rmv.2231>.
- 214 16. Cerutti G, Guo Y, Zhou T, et al. Potent SARS-CoV-2 neutralizing antibodies directed against
215 spike N-terminal domain target a single supersite. *Cell Host Microbe* **2021**; Available at:
216 <http://dx.doi.org/10.1016/j.chom.2021.03.005>.



219 **Figure 1: Variants of concern are overrepresented in vaccine breakthrough SARS-CoV-2**
220 **genomes** A) Cumulative number of breakthrough cases and their Pangolin lineages. B)
221 Proportions of lineages for UWVL sequences collected during the same time period. Relative
222 risk of vaccine escape for each VOC (C) and spike amino acid change (D). Error bars represent
223 95% confidence intervals. * $p < 0.05$, ** $p < 0.01$ (Fisher's Exact Test). VOC: variant of concern
224 (total), VOC-WT: variant of concern without reduced neutralization, VOC-R: variant of concern
225 with reduced neutralization

226

227



228

229 **Supplementary Figure 1.** Heat map showing relative frequencies of variants of concern
230 breakthrough vs. control cases.

231 **Supplementary Table 1: Study groups**

	Vaccine Breakthrough (n=20)	UWVL (n=5174)
Age (years)		
Range	26 - 65	0 - 98
Median	43	30
Mean	43.80	32.572
SD	11.61	16.582
IQR	29.75	14.000
Q1	34.00	21.00
Q2	43.00	30.00
Q3	48.00	44.00
Q4	65.00	98.00
Sex		
Female	13 (65.00%)	2439 (47.14%)
Male	6 (30.00%)	2592 (50.10%)
Unknown	1 (5.00%)	143 (2.76%)
Collection date		
Range	2/23/21 - 4/27/21	2/23/21 - 4/27/21
Median	3/29/2021	4/1/2021
Mean	3/29/2021	3/28/2021
IQR	26.50	24.00
Q1	3/17/2021	3/17/2021
Q2	3/29/2021	4/1/2021
Q3	4/13/2021	4/10/2021
Q4	4/27/2021	4/20/2021
Ct value		
Range	16.00 - 35.86	
Median	20.16	
Mean	21.59	
SD	5.32	
IQR	6.19	
Q1	17.82	
Q2	20.16	
Q3	24.00	
Q4	35.86	

232 SD = standard deviation, IQR = interquartile range, Q1= first quartile, Q2 = second quartile, Q3 = third quartile, Q4
 233 = fourth quartile, Ct = PCR cycle threshold

234

235 **Supplementary Table 2: Variants of concern in case vs. control groups**

Vaccine Breakthrough (n=20)			UWVL (n=5174)				
N	20	%	N	%	Fold Increase	95% CI	P*
B.1.1.7	8	40.00%	1609	31.10%	1.29	[0.75, 2.20]	
B.1.351	1	5.00%	37	0.72%	6.99	[1.01, 48.52]	
B.1.427	2	10.00%	153	2.96%	3.38	[0.90, 12.71]	0.001
B.1.429	8	40.00%	1372	26.52%	1.51	[0.88, 2.59]	
P.1	1	5.00%	337	6.51%	0.77	[0.11, 5.20]	
Non-VOC	0	0.00%	1666	32.20%	--	--	--
Total-VOC	20	100.00%	3508	67.80%	1.47	[1.45, 1.50]	0.001
VOC-reduced affinity	12	60.00%	1899	36.70%	1.63	[1.140, 2.34]	0.037
VOC-not reduced affinity	8	40.00%	1609	31.10%	1.29	[0.750, 2.20]	0.468

236 *Fisher's Exact Test, VOC = variant of concern

7 **Supplementary Table 3: Breakthrough Cases**

Patient	Age range	Sex	Comorbidities	Symptomatic	Vaccine Type	Last Vaccine to Collection Date (Days)	Ct	NextClade Lineage	PANGO Lineage	Spike Amino Changes
P1	40-44	M	Hypertension, non-alcoholic steatohepatitis, hyperlipidemia, obstructive sleep apnea	YES	Pfizer	43	23.40	20C	B.1.427	S13I, W258L, L452R, D614G, C1236F
P2	30-34	F	Unknown	NO	Pfizer	39	20.69	20J/501Y.V3	P.1	L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, V1176F
P3	60-64	F	Diabetes (type II), non-alcoholic steatohepatitis, obstructive sleep apnea	Unknown	Unknown	70	35.86	20C	B.1.429	S13I, W152C, L452R, D614G
P4	26-29	F	Unknown	YES	Pfizer	54	17.56	20C	B.1.427	S13I, W152C, W258L, L452R, D614G
P5	60-64	F	Unknown	YES	Pfizer	66	19.61	20C	B.1.429	S13I, W152C, L452R, D614G, L141-, G142-, V143-
P6	35-39	F	None	YES	Pfizer	47	20.80	20C	B.1.429	S13I, W152C, L452R, D614G
P7	55-59	F	Hypothyroid, mild asthma	YES	Pfizer	66	26.40	20C	B.1.429	S13I, W152C, L452R, D614G
P8	40-44	M	Unknown	YES	Pfizer	55	24.00	20C	B.1.429	S13I, W152C, L452R, D614G
P9	40-44	F	Unknown	YES	Pfizer	77	16.40	20C	B.1.429	W152C, L452R, D614G
P10	50-54	F	None	YES	Pfizer	58	21.20	20I/501Y.V1	B.1.1.7	N501Y, A570D, D614G, P681H, T716I, S982A, D1118H, K1191N, H69-, V70-, Y144-
P11	65-69	F	None	YES	Moderna	44	19.62	20H/501Y.V2	B.1.351	D80A, D215G, L242H, K417N, D614G, A701V, A243-, L244-, H245-
P12	25-29	U	Unknown	YES	Pfizer	80	24.10	20C	B.1.429	S13I, W152C, L452R, D614G
P13	30-34	M	Unknown	NO	Moderna	70	18.90	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-
P14	30-34	M	Unknown	YES	Moderna	73	17.90	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-
P15	45-49	M	None	YES	Pfizer	77	17.45	20I/501Y.V1	B.1.1.7	S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-,

											S:V70-, S:Y144-
P16	45-49	F	Unknown	YES	Moderna	67	18.88	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-	
P17	40-44	M	Unknown	YES	Pfizer	96	16.10	20I/501Y.V1	B.1.1.7	S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-	
P18	45-49	F	Unknown	NO	Pfizer	80	16.00	20I/501Y.V1	B.1.1.7	S:D178H, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-	
P19	45-49	F	Unknown	YES	Moderna	72	24.00	20C	B.1.429	S:S13I, S:P26S, S:W152C, S:L452R, S:D614G	
P20	30-34	F	None	Unknown	Pfizer	112	33.00	20I/501Y.V1	B.1.1.7	S:S98F, S:D138H, S:A344V, S:N501Y, S:A570D, S:D614G, S:P681H, S:T716I, S:S982A, S:D1118H, S:H69-, S:V70-, S:Y144-	

8 F = female, M = male, U = unknown sex, Ct = PCR cycle threshold

9
0